NCT04844619 - KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial | Biotech Hunter

Enrollment

40

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Neovascular GlaucomaNeovascularization

Interventions

DRUG

4mg/ml KDR2-2 suspension eyedrop

"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."

DRUG

16mg/ml KDR2-2 suspension eyedrop

"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."

Trial Locations (1)

51000

Zhongshan Ophthalmic Center, Guangzhou